Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DM1 in advanced HER2+ breast cancer after TKI/HP
NCT06125834Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab emtansine in breast cancer, sponsored by Jiangsu Provincial People's Hospital. Started Jun 2023; status: recruiting.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06125834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06125834.